{
    "clinical_study": {
        "@rank": "67349", 
        "brief_summary": {
            "textblock": "This study is a double-blind, placebo-controlled outpatient trial to improve, through the\n      addition of sertraline (Zoloft),  the abstinence and relapse rates in alcohol- dependent\n      individuals currently taking naltrexone (Revia)."
        }, 
        "brief_title": "Sertraline and Naltrexone for Alcohol Dependence", 
        "completion_date": "September 2002", 
        "condition": "Alcoholism", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets the criteria for alcohol dependence.\n\n          -  Abstinent from alcohol for a period of at least 5 days and not greater than 30 days.\n\n          -  Able to read English and complete study evaluations.\n\n          -  A stable residence and a telephone to ensure that subjects can be located during the\n             study.\n\n        Exclusion Criteria:\n\n          -  Currently meets criteria for substance abuse or dependence with the exception of\n             nicotine dependence.\n\n          -  Current use of disulfiram (Antabuse) or a MAO Inhibitor.\n\n          -  Psychotic or otherwise severely psychiatrically disabled (i.e., depressed, suicidal,\n             current mania).\n\n          -  Major depression at the time of assessment.\n\n          -  Previous treatment with naltrexone (Revia) for alcohol dependence.\n\n          -  Significant underlying medical conditions such as cerebral, renal, thyroid, or\n             cardiac disease.\n\n          -  Abstinent longer than 30 days prior to admission to program.\n\n          -  Hepatocellular disease or elevated bilirubin levels.\n\n          -  Females who are pregnant, nursing, or not using a reliable method of birth control."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "124", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000440", 
            "org_study_id": "NIAAAFAR11222"
        }, 
        "intervention": [
            {
                "intervention_name": "naltrexone (Revia)", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "sertraline (Zoloft)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naltrexone", 
                "Sertraline"
            ]
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Department of Psychiatry, Mount Sinai School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Sertraline and Naltrexone for Alcohol Dependents", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000440"
        }, 
        "source": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2004"
    }, 
    "geocoordinates": {
        "Department of Psychiatry, Mount Sinai School of Medicine": "40.714 -74.006"
    }
}